William Blair & Company’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

William Blair & Company’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51,843	Closed	-$75.7K	–	1860
2022 Q4	$75.7K	Hold	51,843	–	–	﹤0.01%	1520
2022 Q3	$221K	Hold	51,843	–	–	﹤0.01%	1352
2022 Q2	$201K	Hold	51,843	–	–	﹤0.01%	1417
2022 Q1	$247K	Hold	51,843	–	–	﹤0.01%	1434
2021 Q4	$189K	Hold	51,843	–	–	﹤0.01%	1597
2021 Q3	$416K	Hold	51,843	–	–	﹤0.01%	1225
2021 Q2	$588K	Hold	51,843	–	–	﹤0.01%	1094
2021 Q1	$480K	Buy	+51,843	New	+$540K	﹤0.01%	1136

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

William Blair & Company's VIRX Position: Q1 2023 in Review

William Blair & Company sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2023, closing a stake of 51,843 shares — an estimated $75.7K sold.

William Blair & Company first reported a position in VIRX in Q1 2021 and held it in 8 quarters. The position peaked at $588K in Q2 2021. 48 funds tracked by Wall St. Rank hold VIRX as of Q1 2023.

William Blair & Company reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
William Blair & Company sold 51,843 Viracta Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $75.7K.
William Blair & Company first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
William Blair & Company's Viracta Therapeutics, Inc. Common Stock position peaked at $588K in Q2 2021.
48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2023.

Based on William Blair & Company's 13F filing for Q1 2023, filed 12 May 2023.